Fotios (Frank) Michelis, MD, PhD

Clinician Investigator, Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre

Keywords: immune reconstitution, late effects, acute myeloid leukemia (AML), allogeneic stem cell/bone marrow transplant

Reduced Intensity Allogeneic Stem Cell Transplant with Anti-Thymocyte globulin and Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia.
Eur J Haematol. 2019 Aug 26;:
Salas MQ, Prem S, Atenafu EG, Law AD, Lam W, Al-Shaibani Z, Loach D, Kim DDH, Michelis FV, Lipton JH, Kumar R, Mattsson J, Viswabandya A
Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment.
Eur J Haematol. 2019 Aug 16;:
Prem S, Atenafu EG, Avena J, Bautista R, Law A, Lam W, Michelis FV, Kim DDH, Viswabandya A, Lipton JH, Mattsson J, Kumar R
Epstein-Barr virus associated post-transplant lymphoproliferative disorder mimicking acute graft versus host disease.
Eur J Haematol. 2019 Aug 07;:
Prem S, Al-Shaibani Z, Michelis FV, Kim D, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Law A, Lam W
Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant. 2019 Jun 04;:
Shapiro RM, Shin E, Law AD, Lam W, Michelis FV, Viswabandya A, Kumar R, Lipton JH, Messner H, Mattsson J, Kim DDH
Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants.
Eur J Haematol. 2019 Mar 29;:
Prem S, Atenafu EG, Al-Shaibani Z, Loach D, Law A, Lam W, Michelis FV, Thyagu S, Kim DDH, Lipton JH, Kumar R, Viswabandya A
Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
Eur J Haematol. 2019 Apr;102(4):368-374
Pasic I, Da'na W, Lam W, Law A, Lipton JH, Viswabandya A, Kim DD, Thyagu S, Messner HA, Michelis FV
Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.
Biol Blood Marrow Transplant. 2019 Jan 14;:
Michelis FV, Hedley DW, Malhotra S, Chow S, Loach D, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Viswabandya A, Messner HA
Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2018 02;24(2):366-372
Beswick J, Shin E, Michelis FV, Thyagu S, Viswabandya A, Lipton JH, Messner H, Marras TK, Kim DDH
Reduced Intensity Conditioning and Dual T-Lymphocyte Suppression with Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis In Haploidentical Stem Cell Transplants For Hematological Malignancies.
Biol Blood Marrow Transplant. 2018 Jul 12;:
Law AD, Salas MQ, Lam W, Michelis FV, Thyagu S, Kim DDH, Lipton JH, Kumar R, Messner H, Viswabandya A
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
Ann Hematol. 2018 Jun 11;:
Khalil MMI, Messner HA, Lipton JH, Kim DD, Viswabandya A, Thyagu S, Deotare U, Michelis FV

Pages
Clinician Investigator, Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Assistant Professor, Department of Medicine, University of Toronto